LOGO
LOGO

After Recent Expanded Regulatory Wins For YCANTH, Is Verrica Undervalued?

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
vrca 21102025 lt

Dermatology-focused biopharmaceutical company Verrica Pharmaceuticals Inc. (VRCA) grabbed our attention following a series of regulatory and clinical updates that may shape its near-term trajectory.

Company Overview

The West Chester, Pennsylvania-based Verrica specializes in developing treatments for skin diseases with unmet medical needs. Its lead product, YCANTH (cantharidin), is approved in the United States for the treatment of molluscum contagiosum and is progressing toward broader international commercialization.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.